This paper is only available as a PDF. To read, Please Download here.
Recent clinical evidence suggests that repeated use of opioid medications increases
chronic pain in individuals living with HIV. It is important to elucidate the exact
molecular mechanisms of neuropathic pain (NP) in opioid users living with HIV. HIV-related
neuron damage is induced by activating glial cells releasing neurotoxic factors (such
as, TNFα). Chronic morphine use also induces TNFα product. Spinal mitochondrial superoxide
(mtO2●-) plays important role in neuropathic pain. Non-canonical inflammasome, caspase-11
signal pathway is involved in methamphetamine-induced neuron apoptosis. Increased
ROS enhances caspase-11 expression during enteric pathogen infection. In the present
study, we investigated the role of TNFRI, mtO2●- and caspase-11 in a HIV coat glycoprotein
gp120 with morphine (gp120/M)-induced neuropathic pain state. HIV-gp120 with morphine
induced mechanical allodynia lasting for 3 weeks. HIV-gp120/M upregulated the expression
of TNFRI, mitochondrial superoxide, with caspase-11, and down-regulated Sirt3 in the
spinal dorsal horn. TNFRI-/- knockout mice were higher mechanical threshold and longer
thermal latency than that in wildtype mice. Intrathecal administration of antisense
oligonucleotides against TNFRI, Mito-Temple (mitochondrial scavenger of mtO2●-), or
siRNA agonist caspase-11 mRNA reduced mechanical allodynia in the gp120/M neuropathic
pain model. Antisense oligonucleotides against TNFRI reduced the number of MitoSox
(a marker of mtO2●-) positive cells in the SCDH in gp120/M group. The rat neuronal
neuroblast (B35) cell line (ATCC) were treated with rTNFα (10 ng/mL, Peprotech) increased
expression of mtO2●- and caspase-11, and caspase-11 related inflammatory factors such
as, caspase-1, and IL-1β. In conclusions, spinal TNFRI signal plays a significant
role in the HIV gp120-related neuropathic pain state, and provide evidence for a novel
approach to treating chronic pain in opioid users living with HIV. NIH R01DA34749,
R01DA047089, and R01DA047157, and R01DA047157-03S1.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The Journal of PainAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Identification
Copyright
© 2021 Published by Elsevier Inc.